Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 362

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Open access
Kim, Hyoung, Xu, Haineng, George, Erin, Hallberg, Dorothy, Kumar, Sushil, Jagannathan, Veena, Medvedev, Sergey, Kinose, Yasuto, Devins, Kyle, Verma, Priyanka, Ly, Kevin, Wang, Yifan, Greenberg, Roger A., Schwartz, Lauren, Johnson, Neil, Scharpf, Robert B., Mills, Gordon B., Zhang, Rugang, Velculescu, Victor E., Brown, Eric J., Simpkins, Fiona·2020·Nature Communications

Abstract

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by increased ATR-CHK1 activity and sensitivity to ATR inhibition (ATRi). However, PARPi-resistant cells are remarkably more sensitive to ATRi when combined with PARPi (PARPi-ATRi). Sensitivity to PARPi-ATRi in diverse PARPi and platinum-resistant models, including BRCA1/2 reversion and CCNE1-amplified models, correlate with synergistic increases in replication fork stalling, double-strand breaks, and apoptosis. Surprisingly, BRCA reversion mutations and an ability to form RAD51 foci are frequently not observed in models of acquired PARPi-resistance, suggesting the existence of alternative resistance mechanisms. However, regardless of the mechanisms of resistance, complete and durable therapeutic responses to PARPi-ATRi that significantly increase survival are observed in clinically relevant platinum and acquired PARPi-resistant patient-derived xenografts (PDXs) models. These findings indicate that PARPi-ATRi is a highly promising strategy for OVCAs that acquire resistance to PARPi and platinum.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17127-2

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 362

Metadata

Authors
Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., Ly, K., Wang, Y., Greenberg, R. A., Schwartz, L., Johnson, N., Scharpf, R. B., Mills, G. B., Zhang, R., Velculescu, V. E., Brown, E. J., & Simpkins, F.
Venue
Nature Communications
Published
2020-07-24
Volume
11
Issue
1
Pages
3726-3726
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3044025582
Cited by
362
References
69
FWCI
14.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. https://app.cochat.ai/papers/10.1038/s41467-020-17127-2
The paper
Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., Ly, K., Wang, Y., Greenberg, R. A., Schwartz, L., Johnson, N., Scharpf, R. B., Mills, G. B., Zhang, R., Velculescu, V. E., . . . Simpkins, F. (2020). Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nature Communications. https://doi.org/10.1038/s41467-020-17127-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.